Growth inhibition and apoptosis in human Philadelphia chromosome-positive lymphoblastic leukemia cell lines by treatment with the dual PPARα/γ ligand TZD18

Blood

Volumn 107, Issue 9, 2006, Pages 3683-3692

  Liu, Hongyu ^b   Zang, Chuanbing ^b   Fenner, Martin H ^b   Liu, Dachuan ^b   Possinger, Kurt ^b   Koeffler, H Phillip ^b   Elstner, Elena ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; CYCLIN D2; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN E; DNA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MYC PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ANTAGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA ANTAGONIST; PROTEIN BCL 2;

APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CONTROLLED STUDY; DNA BINDING; DOWN REGULATION; ENZYME INHIBITION; GROWTH INHIBITION; HUMAN; HUMAN CELL; LYMPHATIC LEUKEMIA; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; WESTERN BLOTTING;

EID: 33646430295     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-05-2103     Document Type: Article

References (86)

1. Redaelli A, Laskin BL, Stephens JM, Botteman MF, Pashos CL. A systematic literature review of the clinical and epidemiological burden of acute lymphoblastic leukaemia (ALL). Eur J Cancer Care (Engl). 2005;14:53-62.
2. Bassan R, Gatta G, Tondini C, Willemze R. Adult acute lymphoblastic leukaemia. Crit Rev Oncol Hematol. 2004;50:223-261.
3. Ottmann OG, Wassmann B. Imatinib in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukaemia: current status and evolving concepts. Best Pract Res Clin Haematol. 2002;15:757-769.
4. Berger J, Bailey P, Biswas C, et al. Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-γ: binding and activation correlate with antidiabetic actions in db/db mice. Endocrinology. 1996;137:4189-4195.
5. Lehmann JM, Moore LB, Smith-Oliver TA, et al. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator- activated receptor γ (PPAR γ). J Biol Chem. 1995;270:12953-12956.
6. Kliewer SA, Lenhard JM, Willson TM, et al. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation. Cell. 1995;83:813-819.
7. Spiegelman BM. PPAR-γ: adipogenic regulator and thiazolidinedione receptor. Diabetes. 1998;47:507-514.
8. Tontonoz P, Hu E, Graves RA, Budavari AI, Spiegelman BM. mPPAR γ 2: tissue-specific regulator of an adipocyte enhancer. Genes Dev. 1994;8:1224-1234.
9. Konopleva M, Andreeff M. Role of peroxisome proliferator-activated receptor-γ in hematologic malignancies. Curr Opin Hematol. 2002;9:294-302.
10. Elstner E, Mueller C, Koshizuka K, et al. Ligands for peroxisome proliferator-activated receptor γ and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci U S A. 1998;95:8806-8811.
11. Elstner E, Williamson EA, Zang C, et al. Novel therapeutic approach: ligands for PPARγ and retinoid receptors induce apoptosis in bcl-2-positive human breast cancer cells. Breast Cancer Res Treat. 2002;74:155-165.
12. Zang C, Liu H, Posch MG, et al. Peroxisome proliferator-activated receptor γ ligands induce growth inhibition and apoptosis of human B lymphocytic leukemia. Leuk Res. 2004;28:387-397.
13. Liu H, Zang C, Fenner MH, Possinger K, Elstner E. PPARγ ligands and ATRA inhibit the invasion of human breast cancer cells in vitro. Breast Cancer Res Treat. 2003;79:63-74.
14. Braissant O, Foufelle F, Scotto C, Dauca M, Wahli W. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-α, -β, and -γ in the adult rat. Endocrinology. 1996;137:354-366.
15. Staels B, Dallongeville J, Auwerx J, et al. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation. 1998;98:2088-2093.
16. Plutzky J. Emerging concepts in metabolic abnormalities associated with coronary artery disease. Curr Opin Cardiol. 2000;15:416-421.
17. Staels B, Koenig W, Habib A, et al. Activation of human aortic smooth-muscle cells is inhibited by PPARα but not by PPARγ activators. Nature. 1998;393:790-793.
18. Meyer K, Jia Y, Cao WQ, Kashireddy P, Rao MS. Expression of peroxisome proliferator-activated receptor α, and PPARα regulated genes in spontaneously developed hepatocellular carcinomas in fatty acyl-CoA oxidase null mice. Int J Oncol. 2002;21:1175-1180.
19. Canuto RA, Muzio G, Maggiora M, et al. Apoptosis induced by clofibrate in Yoshida AH-130 hepatoma cells: role of HMG-CoA reductase. J Lipid Res. 2003;44:56-64.
20. Muzio G, Maggiora M, Trombetta A, et al. Mechanisms involved in growth inhibition induced by clofibrate in hepatoma cells. Toxicology. 2003;187:149-159.
21. Jiao HL, Zhao BL. Cytotoxic effect of peroxisome proliferator fenofibrate on human HepG2 hepatoma cell line and relevant mechanisms. Toxicol Appl Pharmacol. 2002;185:172-179.
22. Scatena R, Nocca G, Sole PD, et al. Bezafibrate as differentiating factor of human myeloid leukemia cells. Cell Death Differ. 1999;6:781-787.
23. Bronfman M, Ponce C, Rojas S, et al. Enhanced differentiation of HL-60 leukemia cells to macrophages induced by ciprofibrate. Eur J Cell Biol. 1998;77:214-219.
24. Desai RC, Han W, Metzger EJ, et al. 5-aryl thiazolidine-2,4-diones: discovery of PPAR dual α/γ agonists as antidiabetic agents. Bioorg Med Chem Lett. 2003;13:2795-2798.
25. Desai RC, Gratale DF, Han W, et al. Aryloxazolidinediones: identification of potent orally active PPAR dual α/γ agonists. Bioorg Med Chem Lett. 2003;13:3541-3544.
26. Guo Q, Sahoo SP, Wang PR, et al. A novel peroxisome proliferator- activated receptor α/γ dual agonist demonstrates favorable effects on lipid homeostasis. Endocrinology. 2004;145:1640-1648.
27. Naumovski L, Morgan R, Hecht F, et al. Philadelphia chromosome-positive acute lymphoblastic leukemia cell lines without classical breakpoint cluster region rearrangement. Cancer Res. 1988;48:2876-2879.
28. Suchanek KM, May FJ, Robinson JA, et al. Peroxisome proliferator- activated receptor α in the human breast cancer cell lines MCF-7 and MDAMB-231. Mol Carcinog. 2002;34:165-171.
29. Lenardo MJ, Baltimore D. NF-κ (B) a pleiotropic mediator of inducible and tissue-specific gene control. Cell. 1989;58:227-229.
30. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984;22:27-55.
31. Crowe DL, Chandraratna RA. A retinoid X receptor (RXR)-selective retinoid reveals that RXR-α is potentially a therapeutic target in breast cancer cell lines, and that it potentiates antiproliferative and apoptotic responses to peroxisome proliferator-activated receptor ligands. Breast Cancer Res. 2004;6:R546-R555.
32. Forman BM, Chen J, Evans RM. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and delta. Proc Natl Acad Sci U S A. 1997;94:4312-4317.
33. Kehrer JP, Biswal SS, La E, et al. Inhibition of peroxisome-proliferator- activated receptor (PPAR)α by MK886. Biochem J. 2001;356:899-906.
34. Leesnitzer LM, Parks DJ, Bledsoe RK, et al. Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662. Biochemistry. 2002;41:6640-6650.
35. Zang C, Wachter M, Liu H, et al. Ligands for PPARγ and RAR cause induction of growth inhibition and apoptosis in human glioblastomas. J Neurooncol. 2003;65:107-118.
36. Karin M, Ben Neriah Y. Phosphorylation meets ubiquitination: the control of NF-κB activity. Annu Rev Immunol. 2000;18:621-663.
37. Padilla J, Leung E, Phipps RP. Human B lymphocytes and B lymphomas express PPAR-γ and are killed by PPAR-γ agonists. Clin Immunol. 2002;103:22-33.
38. Konopleva M, Elstner E, McQueen TJ, et al. Peroxisome proliferator-activated receptor {γ} and retinoid X receptor ligands are potent inducers of differentiation and apoptosis in leukemias. Mol Cancer Ther. 2004;3:1249-1262.
39. Pizzimenti S, Laurora S, Briatore F, et al. Synergistic effect of 4-hydroxynonenal and PPAR ligands in controlling human leukemic cell growth and differentiation. Free Radic Biol Med. 2002;32:233-245.
40. Jones DC, Ding X, Daynes RA. Nuclear receptor peroxisome proliferator-activated receptor α (PPARα) is expressed in resting murine lymphocytes: the PPARα in T and B lymphocytes is both transactivation and transrepression competent. J Biol Chem. 2002;277:6838-6845.
41. Brockman JA, Gupta RA, Dubois RN. Activation of PPARγ leads to inhibition of anchorage-independent growth of human colorectal cancer cells. Gastroenterology. 1998;115:1049-1055.
42. Kitamura S, Miyazaki Y, Shinomura Y, et al. Peroxisome proliferator-activated receptor γ induces growth arrest and differentiation markers of human colon cancer cells. Jpn J Cancer Res. 1999;90:75-80.
43. KiP1 in human pancreatic carcinoma cells. Cancer Res. 2000;60:5558-5564.
44. Elnemr A, Ohta T, Iwata K, et al. PPARγ ligand (thiazolidinedione) induces growth arrest and differentiation markers of human pancreatic cancer cells. Int J Oncol. 2000;17:1157-1164.
45. Fenner M, Elstner E. Peroxisome proliferatoractivated receptor-γ ligands for the treatment of breast cancer. Expert Opin Investig Drugs. 2005;14:557-568.
46. Mitsiades CS, Treon SP, Mitsiades N, et al. TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. Blood. 2001;98:795-804.
47. Chang TH, Szabo E. Induction of differentiation and apoptosis by ligands of peroxisome proliferator-activated receptor γ in non-small cell lung cancer. Cancer Res. 2000;60:1129-1138.
48. Guan YF, Zhang YH, Breyer RM, Davis L, Breyer MD. Expression of peroxisome proliferator-activated receptor γ (PPARγ) in human transitional bladder cancer and its role in inducing cell death. Neoplasia. 1999;1:330-339.
49. Toyota M, Miyazaki Y, Kitamura S, et al. Peroxisome proliferator- activated receptor γ reduces the growth rate of pancreatic cancer cells through the reduction of cyclin D1. Life Sci. 2002;70:1565-1575.
50. Yin F, Wakino S, Liu Z, et al. Troglitazone inhibits growth of MCF-7 breast carcinoma cells by targeting G1 cell cycle regulators. Biochem Biophys Res Commun. 2001;286:916-922.
51. Lapillonne H, Konopleva M, Tsao T, et al. Activation of peroxisome proliferator-activated receptor γ by a novel synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces growth arrest and apoptosis in breast cancer cells. Cancer Res. 2003;63:5926-5939.
52. Laurora S, Pizzimenti S, Briatore F, et al. Peroxisome proliferator-activated receptor ligands affect growth-related gene expression in human leukemic cells. J Pharmacol Exp Ther. 2003;305:932-942.
53. Nasi S, Ciarapica R, Jucker R, Rosati J, Soucek L. Making decisions through Myc. FEBS Lett. 2001;490:153-162.
54. Hupfeld CJ, Weiss RH. TZDs inhibit vascular smooth muscle cell growth independently of the cyclin kinase inhibitors p21 and p27. Am J Physiol Endocrinol Metab. 2001;281:E207-E216.
55. Wolowiec D, Ciszak L, Kosmaczewska A, et al. Cell cycle regulatory proteins and apoptosis in B-cell chronic lymphocytic leukemia. Haematologica. 2001;86:1296-1304.
56. Deininger MW, Vieira SA, Parada Y, et al. Direct relation between BCR-ABL tyrosine kinase activity and cyclin D2 expression in lymphoblasts. Cancer Res. 2001;61:8005-8013.
57. Jena N, Deng M, Sicinska E, Sicinski P, Daley GQ. Critical role for cyclin D2 in BCR/ABL-induced proliferation of hematopoietic cells. Cancer Res. 2002;62:535-541.
58. King KL, Cidlowski JA. Cell cycle regulation and apoptosis. Annu Rev Physiol. 1998;60:601-617.
59. Koeffler HP. Peroxisome proliferator-activated receptor γ and cancers. Clin Cancer Res. 2003;9:1-9.
60. Michalik L, Desvergne B, Wahli W. Peroxisome-proliferator-activated receptors and cancers: complex stories. Nat Rev Cancer. 2004;4:61-70.
61. Thomas A, El Rouby S, Reed JC, et al. Drug-induced apoptosis in B-cell chronic lymphocytic leukemia: relationship between p53 gene mutation and bcl-2/bax proteins in drug resistance. Oncogene. 1996;12:1055-1062.
62. Nencioni A, Lauber K, Grunebach F, et al. Cyclo-pentenone prostaglandins induce lymphocyte apoptosis by activating the mitochondrial apoptosis pathway independent of external death receptor signaling. J Immunol. 2003;171:5148-5156.
63. Inoue S, Snowden RT, Dyer MJ, Cohen GM. CDDO induces apoptosis via the intrinsic pathway in lymphoid cells. Leukemia. 2004;18:948-952.
64. Petak I, Houghton JA. Shared pathways: death receptors and cytotoxic drugs in cancer therapy. Pathol Oncol Res. 2001;7:95-106.
65. Baeuerle PA, Henkel T. Function and activation of NF-κ B in the immune system. Annu Rev Immunol. 1994;12:141-179.
66. Guttridge DC, Albanese C, Reuther JY, Pestell RG, Baldwin AS Jr. NF-κB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol Cell Biol. 1999;19:5785-5799.
67. Hinz M, Krappmann D, Eichten A, et al. NF-κB function in growth control: regulation of cyclin D1 expression and G0/G1-to-S-phase transition. Mol Cell Biol. 1999;19:2690-2698.
68. Hsia CY, Cheng S, Owyang AM, Dowdy SF, Liou HC. c-Rel regulation of the cell cycle in primary mouse B lymphocytes. Int Immunol. 2002;14:905-916.
69. Romashkova JA, Makarov SS. NF-κB is a target of AKT in anti-apoptotic PDGF signalling. Nature. 1999;401:86-90.
70. Toth CR, Hostutler RF, Baldwin AS Jr, Bender TP. Members of the nuclear factor κ B family transactivate the murine c-myb gene. J Biol Chem. 1995;270:7661-7671.
71. Karin M, Lin A. NF-κB at the crossroads of life and death. Nat Immunol. 2002;3:221-227.
72. Munzert G, Kirchner D, Ottmann O, Bergmann L, Schmid RM. Constitutive NF-κb/Rel activation in Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL). Leuk Lymphoma. 2004;45:1181-1184.
73. Kirchner D, Duyster J, Ottmann O, et al. Mechanisms of Bcr-Abl-mediated NF-κB/Rel activation. Exp Hematol. 2003;31:504-511.
74. Reuther JY, Reuther GW, Cortez D, Pendergast AM, Baldwin AS Jr. A requirement for NF-κB activation in Bcr-Abl-mediated transformation. Genes Dev. 1998;12:968-981.
75. Hamdane M, David-Cordonnier MH, D'Halluin JC. Activation of p65 NF-κB protein by p210BCR-ABL in a myeloid cell line (P210BCR-ABL activates p65 NF-κB). Oncogene. 1997;15:2267-2275.
76. Chen GG, Lee JF, Wang SH, et al. Apoptosis induced by activation of peroxisome-proliferator activated receptor-γ is associated with Bcl-2 and NF-κB in human colon cancer. Life Sci. 2002;70:2631-2646.
77. Okano H, Shiraki K, Inoue H, et al. 15-deoxydelta-12-14-PGJ2 regulates apoptosis induction and nuclear factor-κB activation via a peroxisome proliferator-activated receptor-γ-independent mechanism in hepatocellular carcinoma. Lab Invest. 2003;83:1529-1539.
78. Xu X, Otsuki M, Saito H, et al. PPARα and GR differentially down-regulate the expression of nuclear factor-κB-responsive genes in vascular endothelial cells. Endocrinology. 2001;142:3332-3339.
79. Straus DS, Pascual G, Li M, et al. 15-deoxy-delta 12,14-prostaglandin J2 inhibits multiple steps in the NF-κ B signaling pathway. Proc Natl Acad Sci U S A. 2000;97:4844-4849.
80. Deininger MW, Goldman JM, Lydon N, Melo JV. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood. 1997;90:3691-3698.
81. von Bubnoff N, Peschel C, Duyster J. Resistance of Philadelphia- chromosome positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec): a targeted oncoprotein strikes back. Leukemia. 2003;17:829-838.
82. Ottmann OG, Druker BJ, Sawyers CL, et al. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood. 2002;100:1965-1971.
83. Hoover RR, Mahon FX, Melo JV, Daley GQ. Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336. Blood. 2002;100:1068-1071.
84. Peters DG, Hoover RR, Gerlach MJ, et al. Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia. Blood. 2001;97:1404-1412.
85. Thiesing JT, Ohno-Jones S, Kolibaba KS, Druker BJ. Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells. Blood. 2000;96:3195-3199.
86. Topaly J, Zeller WJ, Fruehauf S. Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells. Leukemia. 2001;15:342-347.